Walter H. Moos leads SRI Biosciences, an organization which integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development.
During his career, Moos has made significant contributions to all stages of drug development, from basic research to the marketplace. Prior to joining SRI in 2005, he was Chairman and CEO of MitoKor (Migenix). Previously, he was a vice president at Chiron (Novartis) and at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert (Pfizer).
Moos has served on the boards of about 20 organizations and in a number of advisory capacities for academic, government, and venture capital groups. He also has edited five books, helped to found multiple scientific journals, and has more than 150 publications and patents.
Moos received his Ph.D. from the University of California Berkeley and an A.B. from Harvard University. He has held adjunct faculty positions at the University of Michigan; the University of California San Francisco; and James Madison University.